ChromaDex Shares Climb on Forecast for 15% Revenue Growth

Dow Jones11-01

By Sabela Ojea

Shares of ChromaDex rose after the company said it expects revenue to rise about 15% this year amid views for growth in its e-commerce business and the launch of its vitamin product line Niagen+.

The stock was up 15% to $4.00 in post-market trading. Through Thursday's close the stock has more-than-doubled this year.

The dietary supplement and food ingredient company, which had previously guided for revenue growth of 10% to 15% in 2024, said it also expects its gross margin to improve slightly this year despite booking higher selling and marketing expenses to drive brand awareness and support new market launches.

ChromaDex's outlook comes after a swing to a profit in what Chief Executive Rob Fried described as the company's best quarter to date following a significant increase in sales.

The company logged third-quarter net profit of $1.9 million, or 2 cents a share, compared with a loss of $959,000, or 1 cent a share, for the same period a year earlier.

Sales jumped 31% to $25.6 million. The third quarter also marked the first sales of ChromaDex's Niagen+ vitamin products, Fried said.

Write to Sabela Ojea at sabela.ojea@wsj.com; @sabelaojeaguix

(END) Dow Jones Newswires

October 31, 2024 19:00 ET (23:00 GMT)

Copyright (c) 2024 Dow Jones & Company, Inc.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2480091378?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-11-01 07:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2480091378","market":"hk","top_or_hot":-1,"title":"ChromaDex Shares Climb on Forecast for 15% Revenue Growth","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Sabela Ojea \n</p>\n<pre>\n \n</pre>\n<p>\n  Shares of ChromaDex rose after the company said it expects revenue to rise about 15% this year amid views for growth in its e-commerce business and the launch of its vitamin product line Niagen+. \n</p>\n<p>\n  The stock was up 15% to $4.00 in post-market trading. Through Thursday's close the stock has more-than-doubled this year. \n</p>\n<p>\n  The dietary supplement and food ingredient company, which had previously guided for revenue growth of 10% to 15% in 2024, said it also expects its gross margin to improve slightly this year despite booking higher selling and marketing expenses to drive brand awareness and support new market launches. \n</p>\n<p>\n  ChromaDex's outlook comes after a swing to a profit in what Chief Executive Rob Fried described as the company's best quarter to date following a significant increase in sales. \n</p>\n<p>\n  The company logged third-quarter net profit of $1.9 million, or 2 cents a share, compared with a loss of $959,000, or 1 cent a share, for the same period a year earlier. \n</p>\n<p>\n  Sales jumped 31% to $25.6 million. The third quarter also marked the first sales of ChromaDex's Niagen+ vitamin products, Fried said. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Sabela Ojea at sabela.ojea@wsj.com; @sabelaojeaguix \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  October 31, 2024 19:00 ET (23:00 GMT)\n</p>\n<p>\n  Copyright (c) 2024 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>ChromaDex Shares Climb on Forecast for 15% Revenue Growth</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nChromaDex Shares Climb on Forecast for 15% Revenue Growth\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-01 07:00 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://dowjonesnews.com/newdjn/logon.aspx?AL=N><strong>Dow Jones</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>By Sabela Ojea \n\n\n \n\n\n  Shares of ChromaDex rose after the company said it expects revenue to rise about 15% this year amid views for growth in its e-commerce business and the launch of its vitamin ...</p>\n\n<a href=\"https://dowjonesnews.com/newdjn/logon.aspx?AL=N\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CDXC","symbol_name":"Chromadex Corporation","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2480091378","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2480091378","pubTimestamp":1730415600,"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Shares of ChromaDex rose after the company said it expects revenue to rise about 15% this year amid views for growth in its e-commerce business and the launch of its vitamin product line Niagen+.The stock was up 15% to $4.00 in post-market trading. Through Thursday's close the stock has more-than-doubled this year.The dietary supplement and food ingredient company, which had previously guided for revenue growth of 10% to 15% in 2024, said it also expects its gross margin to improve slightly this year despite booking higher selling and marketing expenses to drive brand awareness and support new market launches.ChromaDex's outlook comes after a swing to a profit in what Chief Executive Rob Fried described as the company's best quarter to date following a significant increase in sales.The company logged third-quarter net profit of $1.9 million, or 2 cents a share, compared with a loss of $959,000, or 1 cent a share, for the same period a year earlier.Sales jumped 31% to $25.6 million. The","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"CDXC":"Chromadex Corporation"},"translate_title":"ChromaDex股价上涨，预计收入增长15%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CDXC":1},"content_text":"By Sabela Ojea \n\n\n \n\n\n  Shares of ChromaDex rose after the company said it expects revenue to rise about 15% this year amid views for growth in its e-commerce business and the launch of its vitamin product line Niagen+. \n\n\n  The stock was up 15% to $4.00 in post-market trading. Through Thursday's close the stock has more-than-doubled this year. \n\n\n  The dietary supplement and food ingredient company, which had previously guided for revenue growth of 10% to 15% in 2024, said it also expects its gross margin to improve slightly this year despite booking higher selling and marketing expenses to drive brand awareness and support new market launches. \n\n\n  ChromaDex's outlook comes after a swing to a profit in what Chief Executive Rob Fried described as the company's best quarter to date following a significant increase in sales. \n\n\n  The company logged third-quarter net profit of $1.9 million, or 2 cents a share, compared with a loss of $959,000, or 1 cent a share, for the same period a year earlier. \n\n\n  Sales jumped 31% to $25.6 million. The third quarter also marked the first sales of ChromaDex's Niagen+ vitamin products, Fried said. \n\n\n \n\n\n  Write to Sabela Ojea at sabela.ojea@wsj.com; @sabelaojeaguix \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  October 31, 2024 19:00 ET (23:00 GMT)\n\n\n  Copyright (c) 2024 Dow Jones & Company, Inc.","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.2","shortVersion":"4.29.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2480091378"}